ESTRO 2024 - Abstract Book

S5705

RTT - Patient experience and quality of life

ESTRO 2024

thoracic radiotherapy, to eventually facilitate early intervention and improved survival. The primary endpoint of the study was to understand barriers to patient recruitment, study concordance and patient experience.

Material/Methods:

First, the radiotherapy clinical trials team were adequately trained for this extension to their scope of practice. To learn the necessary skills, the team attended an informed consent workshop provided by the NIHR and from this developed a generic local informed consent framework for clinical trials. Trial specific documentation detailing patient approach, consent and study logistics process documents and checklists were formulated to ensure all trial procedures were undertaken as per protocol. The eligibility criteria for the ReCoRd study were: patients receiving thoracic radiotherapy with performance status 0-2; life expectancy >4 months; and ownership of a compatible smartphone. Patients with implanted cardiac devices were excluded. Participants received a Withings ScanWatch and were fitted with a LifeSignals biosensor patch for 72-hours continuous electrocardiogram (ECG) monitoring upon radiotherapy completion. Whilst wearing the patch, participants took ‘on-demand’ ECGs on their ScanWatch every 2-hours for direct comparison with the biosensor ECGs. They wore the ScanWatch for a further 6-weeks and took 2+ ECGs daily. Participants were given a diary card to report symptoms and a paper experience questionnaire. Barriers to recruitment were collected with reasons for decline also noted. The process documents developed during the set-up of the study provided the research radiographers with the necessary tools to conduct all trial procedures appropriately, especially the use of the smart technology which had previously never been used by the team. The radiographers took responsibility for setting the participants up with the ScanWatch and biosensor, ensuring the phone and watch were linked to allow data collection under the study ID, and that participants were confident recording an on-demand 30s ECG with the device. The team approached 124 patients to participate in ReCoRd (Figures 1 & 2); 26% (n=32) declined, 35% (n=44) were ineligible. 39% (n=48) of patients were recruited to the study with 13% of these (n=6/48) withdrawing after consent. Median participant age was 67.5 years (range 47-86). Patients were primarily ineligible for the trial owing to the lack of a smart phone (36/44). Reasons for declining study entry were varied, some stating there was ‘too much Results: